{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:17:03Z","timestamp":1774527423197,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10637-016-0395-y","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T08:45:00Z","timestamp":1475138700000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience"],"prefix":"10.1007","volume":"35","author":[{"given":"Manojkumar","family":"Bupathi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joud","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie","family":"Bean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"395_CR1","unstructured":"Castells MC, Matulonis U (2015) Infusion reactions to systemic chemotherapy. UpToDate"},{"issue":"4","key":"395_CR2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17(4):1141\u20131145","journal-title":"J Clin Oncol"},{"issue":"4","key":"395_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00689458","volume":"35","author":"AA Shlebak","year":"1995","unstructured":"Shlebak AA, Clark PI, Green JA (1995) Hypersensitivity and cross-reactivity to cisplatin and analogs. Cancer Chemother Pharmacol 35(4):349\u2013351. doi:10.1007\/Bf00689458","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"395_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000055363","volume":"61","author":"A Polyzos","year":"2001","unstructured":"Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, Giannopoulos A, Karatzas G, Giannikos L, Sfikakis PP (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61(2):129\u2013133. doi:10.1159\/000055363","journal-title":"Oncology"},{"issue":"13","key":"395_CR5","first-page":"1671","volume":"18","author":"A Gowda","year":"2004","unstructured":"Gowda A, Goel R, Berdzik J, Leichman CG, Javle M (2004) Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 18(13):1671\u20131675 discussion 1676, 1680, 1683\u20131674","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"395_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1385\/CRIAI:24:3:253","volume":"24","author":"GM Shepherd","year":"2003","unstructured":"Shepherd GM (2003) Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 24(3):253\u2013262. doi:10.1385\/CRIAI:24:3:253","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"395_CR7","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","volume":"37","author":"BA Baldo","year":"2014","unstructured":"Baldo BA (2014) Side effects of cytokines approved for therapy. Drug Saf 37(11):921\u2013943. doi:10.1007\/s40264-014-0226-z","journal-title":"Drug Saf"},{"issue":"Suppl 10","key":"395_CR8","doi-asserted-by":"publisher","first-page":"x313","DOI":"10.1093\/annonc\/mds314","volume":"23","author":"M Joerger","year":"2012","unstructured":"Joerger M (2012) Prevention and handling of acute allergic and infusion reactions in oncology. Ann Oncol 23(Suppl 10):x313\u2013x319. doi:10.1093\/annonc\/mds314","journal-title":"Ann Oncol"},{"issue":"6","key":"395_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13(6):725\u2013732. doi:10.1634\/theoncologist.2008-0012","journal-title":"Oncologist"},{"issue":"10","key":"395_CR10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","volume":"24","author":"KM Zanotti","year":"2001","unstructured":"Zanotti KM, Markman M (2001) Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 24(10):767\u2013779","journal-title":"Drug Saf"},{"issue":"5","key":"395_CR11","first-page":"458","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB (1992) Hypersensitivity reactions. Semin Oncol 19(5):458\u2013477","journal-title":"Semin Oncol"},{"issue":"1","key":"395_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000178163","volume":"76","author":"A Polyzos","year":"2009","unstructured":"Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, Polyzos K, Tsigris C, Mantas D, Papachristodoulou A, Nikiteas N, Karavokyros JG, Felekouras E, Griniatsos J, Giannopoulos A, Kouraklis G (2009) Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 76(1):36\u201341. doi:10.1159\/000178163","journal-title":"Oncology"},{"issue":"15","key":"395_CR13","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.ejca.2005.06.021","volume":"41","author":"F Maindrault-Goebel","year":"2005","unstructured":"Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41(15):2262\u20132267. doi:10.1016\/j.ejca.2005.06.021","journal-title":"Eur J Cancer"},{"issue":"12","key":"395_CR14","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","volume":"12","author":"EA Eisenhauer","year":"1994","unstructured":"Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N et al (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12(12):2654\u20132666","journal-title":"J Clin Oncol"},{"issue":"5","key":"395_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","volume":"12","author":"HJ Lenz","year":"2007","unstructured":"Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12(5):601\u2013609. doi:10.1634\/theoncologist.12-5-601","journal-title":"Oncologist"},{"issue":"5","key":"395_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3(5):391\u2013400. doi:10.1038\/nrd1381","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"395_CR17","first-page":"742","volume":"6","author":"R Mehra","year":"2008","unstructured":"Mehra R, Cohen RB, Burtness BA (2008) The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6(10):742\u2013750","journal-title":"Clin Adv Hematol Oncol"},{"issue":"9","key":"395_CR18","first-page":"451","volume":"5","author":"SP Kang","year":"2007","unstructured":"Kang SP, Saif MW (2007) Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol 5(9):451\u2013457","journal-title":"J Support Oncol"},{"issue":"2","key":"395_CR19","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH (2010) Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs 14(2):E10\u2013E21. doi:10.1188\/10.CJON.E10-E21","journal-title":"Clin J Oncol Nurs"},{"issue":"10","key":"395_CR20","doi-asserted-by":"publisher","first-page":"e26333","DOI":"10.4161\/onci.26333","volume":"2","author":"BA Baldo","year":"2013","unstructured":"Baldo BA (2013) Adverse events to monoclonal antibodies used for cancer therapy focus on hypersensitivity responses. Oncoimmunology 2(10):e26333. doi:10.4161\/onci.26333","journal-title":"Oncoimmunology"},{"key":"395_CR21","unstructured":"NCI (2009) Common terminology criteria for adverse events (CTCAE) Version 4.0. NIH"},{"issue":"1","key":"395_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11882-008-0011-0","volume":"8","author":"E Syrigou","year":"2008","unstructured":"Syrigou E, Syrigos K, Saif MW (2008) Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 8(1):56\u201362","journal-title":"Curr Allergy Asthma Rep"},{"key":"395_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14694\/EdBook_AM.2015.35.22","volume":"35","author":"ES Kim","year":"2015","unstructured":"Kim ES (2015) The future of molecular medicine: biomarkers, batTLEs, and big data. American Society of Clinical Oncology educational book \/ ASCO American Society of Clinical Oncology Meeting 35:22\u201327. doi:10.14694\/EdBook_AM.2015.35.22","journal-title":"American Society of Clinical Oncology educational book \/ ASCO American Society of Clinical Oncology Meeting"},{"issue":"8","key":"395_CR24","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/annonc\/mds027","volume":"23","author":"JJ Wheler","year":"2012","unstructured":"Wheler JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Moulder S, Stephen B, Wen S, Kurzrock R (2012) Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson cancer center experience. Ann Oncol 23(8):1963\u20131967. doi:10.1093\/annonc\/mds027","journal-title":"Ann Oncol"},{"issue":"3","key":"395_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0268-960X(03)00005-5","volume":"17","author":"P Campbell","year":"2003","unstructured":"Campbell P, Marcus R (2003) Monoclonal antibody therapy for lymphoma. Blood Rev 17(3):143\u2013152","journal-title":"Blood Rev"},{"issue":"11","key":"395_CR26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood.V112.11.328.328","volume":"112","author":"A Osterborg","year":"2008","unstructured":"Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmen A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJS, Padmanabhan S, Kozak T, Chan G, Davis RL, Losic N, Russell CA, Piotrowska M, Wilms J, Wierda WG (2008) Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial (abstr. Blood 112(11):126\u2013127","journal-title":"Blood"},{"issue":"3","key":"395_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","volume":"11","author":"M Markman","year":"2003","unstructured":"Markman M (2003) Managing taxane toxicities. Support Care Cancer 11(3):144\u2013147. doi:10.1007\/s00520-002-0405-9","journal-title":"Support Care Cancer"},{"issue":"3","key":"395_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1081-1206(10)60078-6","volume":"102","author":"C Lee","year":"2009","unstructured":"Lee C, Gianos M, Klaustermeyer WB (2009) Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 102(3):179\u2013187 . doi:10.1016\/S1081-1206(10)60078-6quiz 187\u2013179, 222","journal-title":"Ann Allergy Asthma Immunol"},{"key":"395_CR29","doi-asserted-by":"crossref","unstructured":"Timoney J, Chung KY, Park V, Trocola R, Peake C, Saltz LB , (2006) Cetuximab use without chronic antihistamine premedication. In: 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Vol 24, No 18S (June 20 Supplement): 13521","DOI":"10.1200\/jco.2006.24.18_suppl.13521"},{"issue":"33","key":"395_CR30","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1200\/JCO.2008.16.3758","volume":"26","author":"H Wilke","year":"2008","unstructured":"Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, Aapro MS, Esser R, Loos AH, Siena S (2008) Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol 26(33):5335\u20135343. doi:10.1200\/JCO.2008.16.3758","journal-title":"J Clin Oncol"},{"issue":"3","key":"395_CR31","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","volume":"17","author":"JC Byrd","year":"1999","unstructured":"Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17(3):791\u2013795","journal-title":"J Clin Oncol"},{"issue":"3\u20134","key":"395_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10555-013-9447-3","volume":"32","author":"BA Baldo","year":"2013","unstructured":"Baldo BA, Pham NH (2013) Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch. Cancer Metastasis Rev 32(3\u20134):723\u2013761. doi:10.1007\/s10555-013-9447-3","journal-title":"Cancer Metastasis Rev"},{"issue":"11","key":"395_CR33","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358(11):1109\u20131117. doi:10.1056\/NEJMoa074943","journal-title":"N Engl J Med"},{"issue":"1","key":"395_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7326\/0003-4819-94-1-66","volume":"94","author":"RB Weiss","year":"1981","unstructured":"Weiss RB, Bruno S (1981) Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 94(1):66\u201372","journal-title":"Ann Intern Med"},{"issue":"2","key":"395_CR35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cea.12237","volume":"44","author":"F Berroa","year":"2014","unstructured":"Berroa F, Lafuente A, Javaloyes G, Ferrer M, Moncada R, Goikoetxea MJ, Urbain CM, Sanz ML, Gastaminza G (2014) The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of peranaesthetic hypersensitivity reactions. Clin Exp Allergy 44(2):270\u2013277. doi:10.1111\/cea.12237","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"395_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/BF01533368","volume":"14","author":"LB Schwartz","year":"1994","unstructured":"Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Vanderzwan JK, Vanderlinden PWG (1994) Development of a new, more sensitive immunoassay for human tryptase - use in systemic-anaphylaxis. J Clin Immunol 14(3):190\u2013204. doi:10.1007\/Bf01533368","journal-title":"J Clin Immunol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0395-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:01:10Z","timestamp":1678510870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0395-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]},"assertion":[{"value":"23 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JH serves as a consultant for Baxter; DH received honoraria for a talk and research funding from Lilly; DK received research funding from Phosplatin Pharma Inc.; FMB received honoraria from Genentech, Roche Diagnostics, and Sysmex, served as a consultant for Genentech, Novartis, Roche, and Inflection Biosciences, and received research funding from Novartis, Astra Zeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, and Bayer; MB, SB, SF, BS, KH, and AN have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potential conflict of interest"}},{"value":"This work was supported by the NIH Clinical and Translational Science Award UL1 RR024148 and by the NIH Cancer Center Support Grant (CCSG) award CA016672 to MD Anderson Cancer Center","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding source"}},{"value":"The study was conducted with the approval of and in accordance with the guidelines of the MD Anderson Cancer Center Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}